Predictive modeling of ARDS mortality integrating biomarker/cytokine, clinical and metabolomic data.

Summary

A multimodal model integrating clinical, cytokine, and metabolomic data predicted ARDS mortality with high accuracy (AUC 0.868 test; 0.959 validation) and perfect specificity for non-survivors in the validation cohort. Metabolomic signatures implicated tryptophan–kynurenine and NAD+/NAMPT pathways, corroborated by porcine sepsis/ARDS lung tissue analyses.

Key Findings

• Multimodal mortality prediction achieved AUC 0.868 (test) and 0.959 (validation) with perfect specificity for non-survivors in validation.
• Early sampling within hours of ICU admission and integration of clinical, cytokine, and metabolomic data improved prognostic performance.
• Metabolomic signatures implicated tryptophan–kynurenine, NAD+/NAMPT, and glycosaminoglycan biosynthesis pathways, corroborated in porcine sepsis/ARDS lung tissues.

Clinical Implications

If externally validated and prospectively tested, the model could enable early risk stratification and guide resource allocation and investigational therapies targeting identified metabolic pathways.

Limitations

• Potential overfitting and need for multicenter external validation and prospective impact studies.
• Exact sample size and cohort diversity are not specified in the abstract.

Future Directions

Prospective, multicenter validation; integration into clinical workflows; interventional trials targeting kynurenine and NAD+/NAMPT pathways in identified high-risk patients.